Creat membership Creat membership
Sign in

Forgot password?

Confirm
  • Forgot password?
    Sign Up
  • Confirm
    Sign In
Creat membership Creat membership
Sign in

Forgot password?

Confirm
  • Forgot password?
    Sign Up
  • Confirm
    Sign In
Collection
For ¥0.57 per day, unlimited downloads CREATE MEMBERSHIP Download

toTop

If you have any feedback, Please follow the official account to submit feedback.

Turn on your phone and scan

home > search >

Distinguished physician-scientist, Dr. Mikhail Blagosklonny, joins Roswell Park Cancer Institute

Author:
None  


Journal:
Cancer Biology & Therapy


Issue Date:
2009


Abstract(summary):

Mikhail (Misha) V.  Blagosklonny, MD, PhD, has been appointed Member/Professor of Oncology at Roswell Park Cancer Institute, Buffalo, NY. His appointment started April 15, 2009. Dr. Blagosklonny is an author of over 170 research articles, reviews and book chapters. He is Founding Editor and Editor-in-Chief of Cell Cycle and also Associate Editor of Cancer Biology & Therapy, Cancer Research, Cell Death & Differentiation, Autophagy, International Journal of Cancer, American Journal of Pathology, and PLOS ONE. His research interests range from molecular and cellular biology to clinical investigations and include signal transduction, cell cycle, cellular senescence, anticancer therapeutics with emphasis on translation of basic science into new anticancer strategies. He extended the study of signal transduction pathways from cancer to aging, revealing potential targets for slowing down aging and age-related diseases.  “Misha is a pre-eminent researcher, who developed unique concepts in cancer biology and therapy ,” according to Andrei V. Gudkov, Senior Vice-President of Basic Science at Roswell Park and Chairman of the Department of Cell Stress Biology. “The presence of Misha will facilitate the development of new anti-cancer strategies and methods of cancer therapy and prevention. Here at Roswell, we are very enthusiastic about his recruitment. We share numerous ideas and approaches, including protection of normal cells from radio- and chemotherapy, selective combinations of anticancer drugs, tissue-specific therapy (anti-tissue therapy) of cancer, and prevention of cancer by slowing down organismal aging”.


Page:
753-752


VIEW PDF

The preview is over

If you wish to continue, please create your membership or download this.

Create Membership

Similar Literature

Submit Feedback

This function is a member function, members do not limit the number of downloads